Alcohol supplementation in rhizomelic chondrodysplasia punctata in the Netherlands

ISRCTN ISRCTN44820021
DOI https://doi.org/10.1186/ISRCTN44820021
Secondary identifying numbers NL736 (NTR746)
Submission date
22/11/2006
Registration date
22/11/2006
Last edited
23/09/2021
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Musculoskeletal Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr A M Bams-Mengerink
Scientific

Academic Medical Center
Department of Pediatry
H8-141
Meibergdreef 9
Amsterdam
1105 AZ
Netherlands

Phone +31 (0)20 5667508
Email a.m.mengerink@amc.uva.nl

Study information

Study designCohort study
Primary study designObservational
Secondary study designCohort study
Study setting(s)Not specified
Study typeScreening
Scientific titleAlcohol supplementation in rhizomelic chondrodysplasia punctata in the Netherlands
Study objectivesPlasmalogens can be synthesised out of batyl alcohol (naturally occuring alkylglycerol) in patients with the peroxisomal disorder Rhizomelic Chondro-Dypslasia Punctata (RCDP), bypassing the peroxisomal steps in the pathway.
Ethics approval(s)Ethics approval received from the local medical ethics committee
Health condition(s) or problem(s) studiedRhizomelic chondrodysplasia punctata
InterventionBatyl alcohol supplementation 5 to 50 mg/kg/day.

The following steps will be taken:
1. Blood sampling
2. X-ray skeleton
3. Dexa scan
4. Magnetic Resonance Imaging (MRI)
5. ElectroEncephaloGram (EEG)
6. Visual Evoked Potential (VEP)
7. Brainstem Auditory Evoked Potentials (BAEP)
8. ElectroMyoGraphy (EMG)
9. SomatoSensory Evoked Potentials (SSEP)
10. Questionnaire on well-being
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Specified
Drug / device / biological / vaccine name(s)Batyl alcohol
Primary outcome measurePlasmalogen content in erythrocytes increases significantly in both severe and milder patients with RCDP.
Secondary outcome measures1. Increase in plasmalogens in sputum
2. Improving quality of life scores (TNO-AZL Preschool children Quality of Life [TAPQOL])
3. Stabilisation or improvement in nerve conduction

Stabilisation in MRI/MRS will be our tertiary endpoint.
Overall study start date01/01/2006
Completion date01/01/2008

Eligibility

Participant type(s)Patient
Age groupNot Specified
SexNot Specified
Target number of participants10
Key inclusion criteria1. Parents or legal representatives must have given written informed consent
2. Patients must have a current diagnosis of RCDP established by biochemical analysis and/or mutation analysis
3. Parents of patients must be willing to fulfil the evaluation program
Key exclusion criteria1. Parents/legal representatives are unwilling to fulfil the evaluation program
2. Intolerability of the drug
3. Concomitant severe disease resulting in very short life expectancy
4. Decision by the patient and/or his/her parents or legal representatives to withdraw from the treatment
Date of first enrolment01/01/2006
Date of final enrolment01/01/2008

Locations

Countries of recruitment

  • Netherlands

Study participating centre

Academic Medical Center
Amsterdam
1105 AZ
Netherlands

Sponsor information

Academic Medical Center (AMC) (The Netherlands)
Hospital/treatment centre

Department of Pediatrics
P.O. Box 22660
Amsterdam
1100 DD
Netherlands

ROR logo "ROR" https://ror.org/03t4gr691

Funders

Funder type

Not defined

Not provided at time of registration

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Editorial Notes

23/09/2021: Proactive update review. No publications found. Search options exhausted.